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ABSTRACT  
Background: Previous reports identifying discordance between multiparameter tests at the 
individual patient level have been largely attributed to methodological shortcomings of multiple 
in silico studies. Comparisons between tests, when performed using actual diagnostic assays, have 
been predicted to demonstrate high degrees of concordance. OPTIMA prelim compared predicted 
risk stratification and subtype classification of different multiparameter tests performed directly 
on the same population.  
Methods: Three hundred thirteen women with early breast cancer were randomised to standard 
(chemotherapy and endocrine therapy) or test-directed (chemotherapy if Oncotype DX recurrence 
score >25) treatment. Risk stratification was also determined with, Prosigna (PAM50), 
MammaPrint, MammaTyper, NexCourse Breast (IHC4-AQUA) and conventional IHC4 (IHC4). 
Subtype classification was provided by Blueprint, MammaTyper and Prosigna.  
Results: Oncotype DX predicted a higher proportion of tumours as low risk (82.1%, 95% confidence 
interval [CI] = 77.8% to 86.4%) than were predicted low/intermediate risk using Prosigna (65.5%, 95% 
CI = 60.1% to 70.9%), IHC4 (72.0%, 95% CI = 66.5 % to 77.5%), MammaPrint (61.4%, 95% CI = 
55.9% to 66.9%) or NexCourse Breast (61.6%, 95% CI = 55.8% to 67.4%). Strikingly, the five tests 
showed only modest agreement when dichotomising results between high versus low/intermediate risk. 
Only 119 (39.4%) tumours were classified uniformly as either low/intermediate risk or high risk, and 
183 (60.6%) were assigned to different risk categories by different tests, although 94 (31.1%) showed 
agreement between four or five tests. All three subtype tests assigned 59.5-62.4% of tumours to luminal 
A subtype, but only 121 (40.1%) were classified as luminal A by all three tests and only 58 (19.2%) 
were uniformly assigned as non-luminal A. Discordant subtyping was observed in 123 (40.7%) 
tumours. 
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Conclusions: Existing evidence on the comparative prognostic information provided by different tests 
suggests current multiparameter tests provide broadly equivalent risk information for the population 
of women with estrogen receptor (ER)-positive breast cancers. However, for the individual patient, 
tests may provide differing risk categorisation and subtype information. 
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INTRODUCTION 
For over 40 years (1-3) the impact of tumour molecular markers on patient outcome and 
treatment response has been central to breast cancer management. Gene-expression profiling (4;5) 
to describe the intrinsic subtypes of breast cancer was followed by the independent development, 
in 2004, of the first multiparameter molecular diagnostic assay stratifying breast cancer patients 
with estrogen receptor (ER) positive disease based on risk of relapse following treatment (6). The 
past decade saw a rapid expansion in the number of such multiparameter molecular residual risk 
tests for breast cancer patients (see (7)). These herald an era of more personalised medicine because 
of their potential to inform rational treatment decisions on a patient-by-patient basis. The initial goal 
was to identify patients who, despite “favourable” clinico-pathological characteristics, have a poor 
outcome following conventional endocrine treatment and to advise aggressive therapy, which may 
reduce relapse risk.  Over time, interest has also grown in the potential for multiparameter assays 
to predict chemo-sensitivity (8;9). These tests may also allow an estimate of the intrinsic 
chemotherapy sensitivity of tumours, reducing the importance of stage information. There are 
women who gain little from chemotherapy and women who have clinically relevant gains. There is 
therefore a rationale for using stratified medicine to identify patients who may safely avoid toxicities 
associated with chemotherapy.  
The OPTIMA trial (7) is designed as a prospective test of the effectiveness of multiparameter 
testing in identifying the sub-group of women with breast cancer (among those who would be routinely 
offered adjuvant chemotherapy based on conventional criteria) whose tumours are intrinsically 
insensitive to chemotherapy and for whom such treatment offers only toxicity and delay in starting 
more effective adjuvant endocrine therapy and radiotherapy without any clinically meaningful 
additional benefit. A key objective of “OPTIMA prelim”, the in-built feasibility phase of OPTIMA, 
was to evaluate the performance of alternative multiparameter tests, to aid selection of a test for 
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the main study that would ensure the results of such a trial be robust and broadly applicable to the 
patient population, both now and in the future. Critical to this decision was the ability to compare 
test performance at both the population and individual patient level. Existing data directly 
comparing individual test performance is limited. A series of studies performing statistical 
comparisons between tests suggest that, at a population level, four tests (IHC4, PAM50, BCI and 
Oncotype DX) provided broadly equivalent prognostic information on the risk of relapse up to five 
years post treatment (10-12). Further studies, based largely on in silico reconstruction of existing 
tests from publically available gene expression datasets suggest a statistically significant degree of 
discordance between signatures at the individual patient level (13-17). These observations are 
predominantly attributed to methodological differences due the in silico reconstruction of 
signatures (15;17). This thesis has not, to date, been robustly tested using actual test 
methodologies. Limited data shows that concordance between different tests in assigning patients 
to similar risk groups is low (10). This is consistent with the marked differences in genes measured 
by different tests (See Supplementary Table 1, available online) and with the relatively modest 
predictive value, in terms of recurrence, offered by these tests at the individual patient level. Here 
we report the direct patient-level comparison of multiple commercial residual risk profiles in the 
OPTIMA prelim study, performed to gather information on their performance.  
 
MATERIALS AND METHODS 
Recruitment and patient samples 
Optimal Personalised Treatment of early breast cancer using Multiparameter Analysis 
preliminary study (OPTIMA prelim, ISRCTN42400492) (18) is a multicentre study that randomly 
assigned women aged ≥40 with ER-positive, human epidermal growth factor receptor 2 (HER2)-
negative early breast cancer and either one to nine involved axillary nodes or tumour size of 30mm or 
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greater (if node-negative) between standard treatment (chemotherapy followed by endocrine therapy) 
and test-directed therapy (7). In the test-directed arm an Oncotype DX test was performed; patients 
with Recurrence Scores (RSs) greater than 25 (“high” risk) were assigned chemotherapy followed by 
endocrine therapy, those with RSs of 25 or lower (“intermediate/low” risk) received endocrine therapy 
alone. Chemotherapy, selected from regimens commonly used in the UK NHS, was specified at patient 
registration. The study was partially blinded so that neither patients nor referring centres were aware 
of whether chemotherapy was assigned on the basis of Oncotype DX RS or by random assignment to 
the standard treatment arm. Central retesting of ER and HER2 status was performed on all patients. 
Following confirmation of eligibility, samples were sent to Genomic Health for Oncotype DX assays 
to be performed with funding from the OPTIMA prelim study.  No patient outcome data is available 
for this analysis. All patients gave written informed consent to participate in the study. The study 
was approved by the South East Coast - Surrey Research Ethics Committee. 
To facilitate the comparison of alternative tests a number of test vendors were approached for 
support (Supplementary Table 2, available online). Ultimately five tests in addition to Oncotype DX 
were included in the OPTIMA prelim study: MammaPrint/BluePrint, Prosigna (PAM50), 
MammaTyper, NexCourse Breast by Aqua (IHC4-AQUA) and IHC4 by conventional 
immunohistochemistry. Multiparameter assays were performed irrespective of patient random 
assignment. Vendors that did not participate expressed concerns about transposing specific tests into 
novel applications. 
 
Residual tumour samples from patients were collected at a central good clinical laboratory 
practice pathology repository (Edinburgh UK). Tissue MicroArrays (TMAs) were constructed as 
previously described (19) using triplicate 0.6mm cores. TMA sections, tissue sections or extracted 
mRNA were provided either to the Ontario Institute for Cancer Research (Prosigna; IHC4: ER, 
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PgR and Ki67 by quantitative image analysis (Ariol) using standard immunohistochemistry [IHC] with 
HER2 testing by in situ hybridization [ISH] at UCL Advanced Diagnostics) or to Genoptix (IHC4-
AQUA), Agendia (MammaPrint/Blueprint) and Stratifyer (MammaTyper). Results from 
individual tests were collated at the Warwick Clinical Trials Unit (CTU) for analysis. 
 
Statistical Analysis 
OPTIMA prelim was designed to recruit 300 patients to enable the kappa value for 
agreement between tests to be estimated with good accuracy. Assuming 70% of patients would be 
assigned to no chemotherapy by the test and the true kappa value was 0·8 (14), this would provide 
a lower 95% confidence limit of 0·73. These numbers were also sufficient to allow for the assumed 
proportion of patients assigned to no chemotherapy to vary from 55% to 80% (lower confidence 
limit for kappa varied from 0·74 to 0·72 respectively). 
The proportion of tumours assigned to risk groups and/or subtypes was determined. The 
kappa coefficient and associated 95% (CI) was used to assess agreement between tests. The 
predicted benefits of endocrine therapy with or without chemotherapy individualised to patients 
were estimated using two nomograms, Adjuvant! (20) (version 8, without correction for HER2 
status) and PREDICT (21-23). A multivariable logistic regression model using stepwise 
elimination was performed to determine factors predicting discordant cases. To explore the post 
hoc hypothesis that individual tests were more likely to agree at the extremes of their ranges, two-
by-two scatterplots for the tests that provide risks scores and agreement charts for the 
categorisation of tumours were constructed (24). Statistical analyses were performed using the 
SAS statistical package (version 9.3; SAS Institute Inc., Cary, NC) and R version 3·0·3 (25). All 
statistical tests were two-sided and a p-value of less than 0.05 was considered statistical significant.  
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RESULTS 
Patients 
Between October 2012 and June 2014, 313 patients were randomly assigned from 35 UK 
hospitals (see the Notes), of whom 302 had samples available for multiparameter testing (Table 
1).   Eleven patients were excluded from multiparameter testing; four withdrew consent, one was 
ineligible and samples for six patients were insufficient for testing (Supplementary Figure 1, 
available online).  
 
Results from predictive nomograms 
The majority of patients recruited were either at intermediate (74.8%) or high (21.2%) risk 
using the Nottingham Prognostic Index (NPI) (26). All 12 patients with lower risk NPI scores 
(<3·4) had tumours 3·0 cm or larger in size. The median 10 year overall survival estimated by 
PREDICT (21-23) or Adjuvant! (20) differed by 6.2% to 8.4%  reflecting expected differences 
between the risk estimate provided by these tools (Table 2). 
 
Multiparameter tests 
Results from all tests were available for 236 (78.1%) patients.  One patient on the standard 
arm had insufficient invasive tumour for Oncotype DX testing, but sufficient for alternative testing. 
Test results were unobtainable from Prosigna for three patients; from MammaTyper for four 
patients; from MammaPrint for four patients and BluePrint for seven patients. IHC4 and IHC4-
AQUA could not be determined for 45 (14.9%) and 31 (10.3%) patients respectively, reflecting 
use of TMAs for this assessment.  
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Risk Scores 
Five tests provided quantitative or semi-quantitative risk scores and a pre-defined 
categorised risk assessment (low, intermediate, high). For OPTIMA prelim, Oncotype DX RS was 
dichotomised around 25 separating “low/intermediate” from “high” risk cases as only patients with 
a high risk of recurrence were allocated chemotherapy (Table 3). Using this approach for all tests 
(Supplementary Methods, available online), the proportion of cases classified as low/intermediate 
risk for Oncotype DX was 82.1% (95% CI = 77.8% to 86.4%), 72.0% (95% CI = 66.5% to 77.5%) 
for IHC4, 65.6% (95% CI = 60.1% to 70.9%) using Prosigna risk of recurrence score including 
proliferation and tumour size, 61.6% (95% CI = 55.8% to 67.4%) for IHC4-AQUA, and 61.4% 
(95% CI = 55.9% to 66.9%) for MammaPrint (Table 3).  
Agreement between tests when patients were subdivided into combined low/intermediate 
versus high-risk groups using predefined cut-points was modest; Kappas ranged from 0·33 (95% 
CI = 0·21 to 0·44) between MammaPrint and IHC4 to 0·60 (95% CI = 0·50 to 0·70) between IHC4 
and IHC4-AQUA (Table 4, Supplementary Table 3, available online). Only 119 (39.4%) tumours 
were uniformly classified as either low/intermediate or high by all five test; 30.8% (n=93) tumours 
were classified as low/intermediate risk by all tests, a further 8.6% (n=26) classified as high risk 
by all tests. The majority (60.6%; n=183) of tumours gave no consensus result across all five tests. 
However for 31.1% of tumours (n=94) agreement was observed in four of the five tests. There 
were also no clear differences between tests in terms of the agreement with other tests (Table 5). 
No statistically significant differences in clinico-pathological features between tumours that were 
concordant or discordant were observed (Supplementary Table 4, available online). There is no 
evidence from the scatterplots of risk scores that individual tests were more likely to agree at the 
extremes of their ranges (Supplementary Figure 2, available online). Disagreement spanning one 
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of three risk categories was common, e.g. low risk to intermediate risk, and disagreement spanning 
two categories was not infrequent, i.e. low risk to high risk (Figure 1; Supplementary Table 5, 
available online). An exploratory analysis using a categorisation of low versus intermediate/high 
risk to more closely reflect current test usage was performed (Supplementary Tables 6-7, available 
online) again modest agreement between tests was observed. 
 
Intrinsic Subtypes  
The three tests that provide subtype information categorised similar proportions of patients 
as having “luminal A” tumours (BluePrint: 60.7%, 95% CI = 55.2% to 66.3%, Prosigna: 59.5%, 
95% CI = 53.9% to 65.1% and MammaTyper (combined luminal A and low-risk luminal B): 
62.4%, 95% CI = 56.9% to 67.9%). Thirteen (4.3%) patients were classified as having HER2 
enriched/positive tumours by at least one test. Two (0.7%) patients had basal like tumours using 
Prosigna™ subtyping; one of whom also had a basal like tumour using BluePrint™ but triple 
negative breast cancer using MammaTyper™. All these patients were classified as ER-positive 
and HER2-negative on central review. Agreement between all three tests providing subtype 
assignment was obtained for 179 (59.3%) patients; 121 (40.1%) tumours were classified as luminal 
A; 58 (19.2%) as all other subtypes. Discordant results across these tests were seen in 123 (40.7%) 
patients. Moderate agreement between tests was confirmed by Kappa statistics of 0·39 (95% CI = 
0·29 to 0·50) between BluePrint and MammaTyper, 0·44 (95% CI = 0·34 to 0·54) between 
Prosigna and MammaTyper, and 0·55 (95% CI = 0·45-0 to 64) between BluePrint and Prosigna 
subtype.  
 
Assessing relationship between the Prosigna subtyping and risk of recurrence score  
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Prosigna is unique amongst the multiparameter assays evaluated in providing both a subtype 
and a continuous risk of recurrence score (ROR) with predefined risk categories derived from an 
identical set of genes. All 178 tumours classified as luminal A had a ROR score below the 
predefined high risk cut-point, and none of the 113 luminal B tumours were classified as low-risk 
(Table 6). Eight tumours, all of which were centrally confirmed as ER-positive/HER2-negative 
were categorised into either the basal-like (n=2) or HER2-like (n=6) subtypes and these were either 
intermediate or high risk by ROR score respectively. 
 
DISCUSSION 
The evaluation of candidate multiparameter tests within OPTIMA prelim to determine the 
best assessment of risk stratification for the main OPTIMA study presented an interesting 
challenge given: 1) Evidence that these tests provide broadly similar prognostic information at the 
population level (26); 2) The use of markedly different gene panels to estimate the same endpoint; 
3) The use of different technologies including immunohistochemistry, polymerase chain reaction 
(PCR), quantitative and semi-quantitative array-based technologies.  
Previous in silico comparisons of multiple gene signatures have identified statistically 
significant discordance between different “diagnostic tests” (13;15-17). However, to date, this has 
been attributed to sub-optimal comparisons, since in the majority of studies genomic prediction 
scores have been estimated from published expression profiles. It has been argued that, in any 
direct comparison of validated diagnostic genomic assays, a high level of concordance could and 
should be obtained (14). In the current study we performed such a direct comparison, each 
commercial assay was performed as prescribed by the relevant manufacturer (although the AQUA-
IHC4 assay used TMAs for convenience). What is striking is that, amongst five tests with robust 
independent technical and clinical validation as predictors of residual risk (MammaPrint, 
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Oncotype DX, Prosigna, IHC4 and IHC4-AQUA) and three that measure a recognised risk factor 
(molecular subtype) there is marked disagreement across all tests. Indeed for all tests the level of 
agreement was “moderate” as defined by Prat et al, reaching only level 3 reproducibility (қ0.40-
0.59) (14). This suggests that agreement for risk classification between different molecular tests 
applied to the same patient sample is on the level of agreement for pathological assessment of 
tumour grade.  
The observed disagreement in risk categorisation for 60.6% of tumours raises questions as 
to how patient management may be impacted by the choice of test used for risk stratification. 
Interestingly there does not seem to be better correlation between tests at the extremes of their 
ranges (the very low and high risk tumours in our cohort) than in the mid-range. It was less 
common, although not infrequent, for tumours placed into the lowest risk group by one test to be 
assigned into the highest risk group by another.  
Each test is independently validated and adopted for prediction of risk of recurrence, so 
what should we do when they disagree?  Paradoxically the result of this study can be viewed as 
either predictable or unexpected, depending on perspective. From a purely biological and technical 
perspective it is entirely predictable that tests which measure fundamentally different genes using 
different technologies give dissimilar results even when each individual assay remains technically 
valid. For example MammaPrint and Prosigna, despite measuring the broadest range of genes (70 
and 50 respectively) have only three genes in common and use different technical approaches 
(27;28). Even those tests measuring the same genes (IHC4, IHC4-AQUA and MammaTyper) use 
different technologies (PCR versus IHC) or different antibodies, detection and quantification 
methods.  
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From a clinical perspective the disagreement between multiple tests each assessing residual 
risk is highly perplexing. The disagreement extends to an inability to demonstrate strong 
agreement on molecular subtyping between tests, which again seems counter-intuitive. However, 
it is less surprising that disagreement between molecular subtyping, in this context predominantly 
between luminal A and luminal B, should exist in the absence of any clinical or molecular 
agreement as to the true boundary between a “luminal A” and “luminal B” cancer (16). Again, the 
Prosigna and BluePrint tests for subtyping have minimal gene overlap with only seven genes in 
common.  
What about risk prediction? The prediction of disease recurrence based on clinico-
pathological and molecular features of a cancer is notoriously challenging within populations and 
even more so at the individual patient level. Biologically and clinically aggressive cancers which, 
if left untreated, are destined to progress may be “cured” by surgery, radiotherapy, chemotherapy 
or endocrine therapy. Tests predicting risk therefore face an important challenge in that they seek 
to measure both the risk of recurrence based on the biology of tumours and must function within 
a clinical setting where biology may reflect risk that is not realised due to medical intervention. 
What then can we learn from comparisons between validated assays that seek to stratify patients 
by risk of recurrence, if indeed we can learn anything? We argue that there is value in such 
comparisons, even in the absence of outcome data. Each test applied in this study is externally 
validated and adopted or available for adoption in multiple clinical jurisdictions (6;27-32). 
However none is, or claims to be, the ultimate discriminator of risk for patients. This study suggests 
there is more than one way of predicting residual risk.  
All studies have limitations. While unable to determine subtle nuances in the performance 
of different tests within this population, we also recognise that existing data, both from the original 
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studies validating individual tests and from comparisons, at a population level, of test performance 
in a single population (10-12) cannot provide a clear discrimination between them. No outcome 
data from OPTIMA prelim were available at the time of analysis. As the sample size is 
comparatively small it is highly unlikely that it will prove possible to compare the ability of the 
tests studied here to predict patient outcome. 
In conclusion, in the widest and most comprehensive patient level direct diagnostic 
comparisons to date between multi-parametric tests of “residual risk” (after local treatment and 
endocrine therapy) we present further data that the proportions of patients identified as low, 
intermediate or high risk are broadly similar irrespective of which test is employed. However, both 
with respect to risk stratification and molecular sub-typing, marked differences were observed 
when categorisation of individual patients was considered. Such data, when considered with 
existing data on efficacy comparisons between different tests, support the conclusion that many 
current risk stratification tools are broadly equivalent and that further improvements in both 
prediction of relapse risk and therapeutic targeting would be of clinically significant value for 
patients at high risk of disease relapse (14). 
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Table 1: Characteristics of the 302 patients 
Characteristic 
Total 
n % 
Age years, Median(Range) 58 (40-78) 
Menopausal status of participant   
Pre/peri-menopausal 97 32.1 
Postmenopausal 205 67.9 
Number of involved nodes   
None 57 18.9 
1-3 192 63.6 
4-9 42 13.9 
Positive sentinel node biopsy without clearance surgery 11 3.6 
Histological grade   
1 19 6.3 
2 201 66.6 
3 82 27.1 
Largest tumour size in mm, Median(Range) 28 (2-170) 
<=30mm 172 57.0 
>30mm 130 43.0 
Lymphovascular invasion reported   
No 169 56.0 
Yes 122 40.4 
Not Known 11 3.6 
Tumour type   
Ductal 214 70.9 
Lobular 65 21.5 
Tubular/Cribriform 2 0.7 
Mucinous 4 1.3 
Micropapillary 1 0.3 
Mixed 16 5.3 
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Table 2: Clinical risk of patients (n=302) 
Risk tool Total 
Nottingham Prognostic Index, median (range) 4·6 (2·8-8·2) 
≤3.4, No. (%) 12 (4.0) 
>3.4 - ≤5.4, No. (%) 226 (74.8) 
>5.4, No. (%) 64 (21.2) 
PREDICT 10 year overall survival, median (range), % 
Endocrine therapy only 77·0 (25·1-94·6) 
Chemotherapy and endocrine therapy 82·6 (39·8-95·9) 
Additional benefit of chemotherapy 5·5 (1·2-25·8) 
Adjuvant! 10 year risk overall survival, median (range), %  
Endocrine therapy only 68·6 (25·4-90·4) 
Chemotherapy and endocrine therapy 76·4 (31·0-93·6) 
Additional benefit of chemotherapy 6·8 (1·2-25·8) 
Adjuvant! 10 year relapse free survival, median (range), % 
Endocrine therapy only 60·5 (22·0-82·1) 
Chemotherapy and endocrine therapy 72·9 (29·1-89·4) 
Additional benefit of chemotherapy 10·5 (2·7-33·3) 
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Table 3: Risk categorisation by each test 
Risk group Oncotype DX* MammaPrint† Prosigna IHC4 
IHC4-
AQUA‡ 
No (%) 301 (99·7%) 298 (98.9%) 299 (99.0%) 257 (85.1%) 271 (89.7%) 
Low risk 163 (54.2%) 183 (61.4%) 108 (36.1%) 62 (24.1%) 87 (32.1%) 
Intermediate risk  84 (27.9%) -- 88 (29.4%) 123 (47.9%) 80 (29.5%) 
Mid risk -- -- -- -- 55 (20.3%) 
High risk 54 (17.9%) 115 (38.6%) 103 (34.5%) 72 (28.0%) 49 (18.1%) 
 
 
Table 3  
*Oncotype DX is divided into three risk groups with intermediate defined as Recurrence Score 
18-25 for the current analysis.  
†MammaPrint divides tumours into two risk groups only.  
‡IHC4-AQUA divides tumours into four risk groups: low, low-mid (here called intermediate), 
mid and high (combined as high risk). 
32 
Manuscript submitted 17 February 2016 - FINAL 
 Table 4: Kappa statistics and 95% confidence interval (CI) for tests providing risk 
predictions* 
Test 
MammaPrint 
(Low), Kappa 
statistic (95%CI) 
Prosigna 
(Low/ 
Intermediate), 
Kappa statistic 
(95%CI) 
IHC4 
(Low/ 
Intermediate), 
Kappa statistic 
(95%CI) 
IHC4-AQUA† 
(Low/Low-
Mid), Kappa 
statistic 
(95%CI) 
Oncotype DX 
(Recurrence Score ≤25) 
0·40  
(0·30-0·49) 
0·44 
(0·33-0·54) 
0·53  
(0·41-0·65) 
0·40 
(0·30-0·51) 
MammaPrint -- 0·53 
(0·43-0·63) 
0·33 
(0·21-0·44) 
0·42 
(0·30-0.53) 
Prosigna 
(Low/Intermediate) 
-- -- 0·39 
(0·27-0·50) 
0·43 
(0·31-0·54) 
IHC4 
(Low/Intermediate) 
-- -- -- 0·60 
(0·50-0·70) 
 
 
Table 4  
*Kappa statistics are for agreement between categorisation into combined low and intermediate 
risk versus high risk.  
†IHC4-AQUA mid risk and high risk are combined for this analysis. 
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Table 5: Number of tests agreeing with each test 
 
Number of 
other tests 
agreed with 
test 
Oncotype DX, 
No (%) 
Prosigna, 
No (%) 
MammaPrint, 
No (%) 
IHC4,  
No (%) 
IHC4-AQUA, 
No (%) 
4 119 (39.4%) 119 (39.4%) 119 (39.4%) 119 (39.4%) 119 (39.4%) 
3 84 (27.8%) 77 (25.5%) 73 (24.2%) 67 (22.2%) 75 (24.8%) 
2 54 (17.9%) 52 (17.2%) 47 (15.6%) 36 (11.9%) 33 (10.9%) 
1 31 (10.3%) 33 (10.9%) 34 (11.2%) 25 (8.3%) 27 (9.0%) 
0 13 (4.3%) 18 (6.0%) 25 (8.3%) 10 (3.3%) 17 (5.6%) 
Missing 1 (0.3%) 3 (1.0%) 4 (1.3%) 45 (14.9%) 31 (10.3%) 
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Table 6: Relationship between Prosigna subtyping and the continuous risk of recurrence (ROR) 
score  
Prosigna test result 
Subtype 
Luminal A 
No (%) 
Luminal B 
No (%) 
Basal like 
No (%) 
HER2 enriched  
No (%) 
No. of patients 178 (59.5%) 113 (37.8%) 2 (0.7%) 6 (2.0%) 
Median ROR (Inter-quartile range) 
 Range 
37 (28-44) 
5-59 
70 (63-78) 
43-96 
53 (47-58) 
47-58 
76 (72-78) 
64-84 
Risk Groups      
Low Risk  108 (60.7%) 0 0 0 
Intermediate Risk  70 (39.3%) 16 (14.2%) 2 (100%) 0 
High Risk  0 97 (85.8%) 0 6 (100%) 
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Figure Legend 
Figure 1: Agreement charts for two by two comparison of tests according to risk groups. A) 
Prosigna against Oncotype DX; B) IHC4 against Oncotype DX; C) IHC4-AQUA against 
Oncotype DX; D) IHC4 against Prosigna; E) IHC4-AQUA against Prosigna; F) IHC4 against 
IHC4-AQUA. Only tests that provide three risk categories are included in this analysis. The 
Oncotype DX intermediate risk group is defined as RS 18-25. The IHC4-AQUA mid risk group 
was combined with the high risk group. Rectangles are drawn for each level of the test outcomes, 
i.e. low, intermediate and high risk, based on the row and column cumulative totals. Thus for the 
low risk rectangle of the test 1 vs test 2 comparison, all tumours categorised as low risk by either 
test are included. The boundaries of the rectangles along both axes represent the number of 
tumours that were categorised as that outcome for each test. Black squares within the rectangles 
represent exact agreement between the levels of the two tests, e.g. both low scores, and are of 
size based on the cell frequencies and located according to the cumulative totals of the previous 
levels. Grey rectangles represent partial agreement, where the scores from one test are within one 
level of those from the other test, i.e. a low score on one test but intermediate on the other test. 
White areas within the rectangle reflect disagreement by more than level, i.e. low scores on one 
test and high scores on the other test. 
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Manuscript title: Comparing breast cancer multiparameter tests in the UK OPTIMA prelim trial: All 
tests are equal – none are more equal than others 
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Supplementary Methods 
For analysis, risk groups pre-defined by the test vendor were used except as described below. 
Oncotype DX: Tumours are divided into three risk groups according to Recurrence Score (RS) where 
the intermediate risk group is defined as RS:18-31. Within OPTIMA prelim, a Recurrence Score cut-off of 
>25 vs. ≤25 was selected as the threshold for allocation of patients to chemotherapy or to no chemotherapy. 
For consistency we used the same cut-point. Tumours with an RS >25 were considered high-risk. For analyses 
that required two risk groups, tumours with RS ≤25 were treated as low risk. For analyses that required three 
risk groups, tumours with RS 18-25 were defined as intermediate risk and low risk was defined as RS <18. 
Prosigna: All analyses used the risk of recurrence score including proliferation and tumour size (ROR-
PT) with the vendor’s predefined risk groups. 
MammaPrint: The test vendor divides tumours into two groups, low and high risk and does not provide 
a numerical score. This test therefore could not be included in the agreement chart and scatter plot analyses.  
NexCourse Breast by AQUA (IHC4-AQUA): There are four pre-defined risk groups; low risk, low-
mid risk, mid risk and high risk groups. For analyses that required three risk groups, the mid risk group with 
a 19%-24% risk of recurrence were combined with the high risk group with a 25% risk of recurrence. 
MammaTyper: This test provides subtype information but divides luminal B tumours into intermediate 
and high risk groups. MammaTyper classified far fewer OPTIMA prelim patients as luminal A than Prosigna 
and BluePrint. Therefore on the grounds of clinical applicability (plausibility) we chose to include the 
MammaTyper intermediate-risk luminal B group in the luminal A group. 
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Supplementary Table 1: Gene lists and gene overlap for the individual tests* 
Prosigna 
Oncotype 
DX MammaPrint IHC4 MammaTyper 
ACTR3B KRT5 BAG1* AA555029_RC 
GRHL2 
LOC100131053† 
RASSF7 ERBB2* ERBB2* 
ANLN MAPT BCL2* ALDH4A1 GSTM3 RECQL5 ESR1* ESR1* 
BAG1* MDM2 BIRC5* AP2B1 HRASLS RFC4 MKi67* MKi67* 
BCL2* MELK* CCNB1* AYTL2 IGFBP5 RTN4RL1 PGR* PGR* 
BIRC5* MIA CD68 BBC3 JHDM1D RUNDC1   
BLVRA MKI67* CTSL2 C16orf61 (CMC2†) KNTC2* (NDC80*†) SCUBE2*   
CCNB1* MLPH ERBB2* 
C20orf46 
(TMEM74B) 
LETMD1 SERF1A   
CCNE1 MMP11* ESR1* C9orf30 (TMEFF1†) LGP2 SLC2A3   
CDC20 MYBL2* GRB7* CCNE2 LIN9 SPEF1   
CDC6 MYC GSTM1 CDC42BPA LOC100288906 STK32B   
CDCA1 NUF2† NAT1 MKI67* CDCA7 LOC730018 STMN1    
CDH3 ORC6L MMP11 CENPA MCM6 TGFB3    
CENPF PGR* MYBL2 COL4A2 MELK* TSPYL5    
CEP55 PHGDH PGR* DCK MMP9 UCHL5    
CXXC5 PTTG1 SCUBE2* DIAPH3 MS4A7 WISP1    
EGFR RRM2 STK15 DTL MTDH ZNF533    
ERBB2* SFRP1   EBF4 MYRIP      
ESR1* SLC39A6 TFRC† ECT2 NMU      
EXO1 TMEM45B RPLPO† EGLN1 NUSAP1      
FGFR4 TYMS GUS† ESM1 ORC6L (ORC6†)      
FOXA1 UBE2C GAPDH† EXT1 OXCT1      
FOXC1 UBE2T ACTB† FGF18 PALM2      
GPR160    FLT1 PECI      
GRB7* MRPL19†   GMPS PITRM1      
KIF2C PSMC4   GNAZ PRC1      
KNTC2* 
NDC80*† 
SF3A1†   GPR126 QSCN6L1      
KRT14 ACTB†   GPR180 RAB6B      
KRT17 RPLP0†           
 
*Genes appear in more than one test.  
†Genes that are used for normalisation and do not form part of the test.  
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Supplementary Table 2: Commercial multiparameter assays considered for inclusion in OPTIMA 
prelim 
Test name (Designation) Manufacturer 
Included in 
OPTIMA prelim 
Breast Cancer Index (BCI)  bioTheranostics/Qiagen, Limburg, Netherlands No 
Molecular Grade IndexSM bioTheranostics/Qiagen, Limburg, Netherlands No 
Endopredict®  Sividon Diagnostics, Köln No 
Genomic Grade Index Bordet Institute No 
MammaPrint®/ BluePrint®/ 
TargetPrint® 
Agendia, Irvine, California Yes 
Mammastrat® Clarient/GE Healthcare, Aliso Viejo, California No 
MammaTyperTM Stratifyer/BioNTech Diagnostics, Mainz, 
Germany 
Yes 
NexCourse® Breast by Aqua 
(IHC4-AQUA) 
Genoptix Medical Laboratories, Carlsbad, 
California 
Yes 
Prosigna™ (PAM50) NanoString Technologies, Seattle, Washington Yes 
 
  
41 
 
Supplementary Table 3: Agreement between tests comparing low/intermediate risk versus high risk 
groups using pre-defined cutpoints. 
 Risk Group   
 Low/Intermediate High Total % 
concordance*  Oncotype DX†   
MammaPrint     
Low 177 6 183 96.7% 
High 70 44 114 38.6% 
Total 247 50 297  
% concordance 71.7% 88.0%   
 Oncotype DX†   
Prosigna      
Low/Intermediate 187 8 195 95.9% 
High 59 44 103 42.7% 
Total 246 52 298  
% concordance 76.0% 84.6%   
 Oncotype DX†   
IHC4     
Low/Intermediate 174 11 185 94.1% 
High 33 39 72 54.2% 
Total 207 50 257  
% concordance 84.1% 78.0%   
 Oncotype DX†   
IHC4-AQUA     
Low/Low-Mid 161 6 167 96.4% 
Mid/High 62 41 103 39.8% 
Total 223 47 270  
% concordance 72.2% 87.2%   
 MammaPrint   
Prosigna      
Low/Intermediate 157 39 196 80.1% 
High 25 74 99 74.7% 
Total 182 113 295  
% concordance 86.3% 65.5%   
 MammaPrint   
IHC4     
Low/Intermediate 129 55 184 70.1% 
High 23 47 70 67.1% 
Total 152 102 254  
% concordance 84.9% 46.1%   
 MammaPrint   
IHC4-AQUA     
Low/Low-Mid 130 36 166 78.3% 
Mid/High 38 65 103 63.1% 
Total 168 101 269  
% concordance 77.4% 64.4%   
 Prosigna   
IHC4     
Low/Intermediate 137 47 184 74.5% 
High 22 48 70 68.6% 
Total 159 95 254  
% concordance 86.2% 50.5%   
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 Prosigna   
IHC4-AQUA     
Low/Low-Mid 136 30 166 81.9% 
Mid/High 41 61 102 59.8% 
Total 177 91 268  
% concordance 76.8% 67.0%   
 IHC4   
IHC4-AQUA     
Low/Low-Mid 140 9 149 94.0% 
Mid/High 35 60 95 63.2% 
Total 175 69 244  
% concordance 80.0% 87.0%   
* Concordance is calculated as the percentage of patients that have been classified in the same risk group by 
both tests out of the row or column total respectively. 
†The Oncotype DX low/intermediate risk group is defined as RS≤25.  
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Supplementary Table 4: Characteristics of the patients according to agreement across the five tests 
providing risk (Oncotype DX, Prosigna, MammaPrint, IHC4 and IHC4-AQUA) 
Characteristic 
Test all agree 
low/ 
interemdiate 
risk 
Test all agree 
high risk 
Disagree in at 
least one test 
No % No % No % 
No. of patients 93 30.8 26 8.6 183 60.6 
Age years, Median(Range) 58 (43-78) 57 (42-76) 57 (40-78) 
Menopausal status of participant       
 Pre/peri-menopausal 30 32.3 7 26.9 60 32.8 
 Postmenopausal 63 67.7 19 73.1 123 67.2 
Number of involved nodes       
 None 18 19.3 5 19.2 34 18.6 
 1-3 54 58.1 15 57.7 123 67.2 
 4-9 16 17.2 6 23.1 20 10.9 
 +ve sentinel node biopsy without clearance 
surgery 
5 5.4 0 0 6 3.3 
Histological grade       
 1 or 2 87 93.5 6 23.1 127 69.4 
 3 6 6.5 20 76.9 56 30.6 
Tumour size in mm, Median(Range) 26 (7-110) 34 (8-70) 27 (2-170) 
Lymphovascular invasion reported       
 No 55 59.2 9 34.6 105 57.4 
 Yes 35 37.6 16 61.5 71 38.8 
 Not Known 3 3.2 1 3.9 7 3.8 
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Supplementary Table 5 Agreement between pre-specified risk groups* 
 Risk group   
 Low Intermediate High Total % concordance 
 Oncotype DX RS†   
Prosigna       
Low 80 26 2 108 74.1% 
Intermediate 55 26 6 87 29.9% 
High 27 32 44 103 42.7% 
Total 162 84 52 298  
% concordance 49.4% 31.0% 84.6% kappa 0.24 (95% CI: 0.17-0.33) 
 Oncotype DX RS†   
IHC4       
Low 50 11 1 62 80.6% 
Intermediate 73 40 10 123 32.5% 
High 13 20 39 72 54.2% 
Total 136 71 50 257  
% concordance 36.8% 56.3% 78.0% kappa 0.27 (95% CI: 0.19-0.36) 
 Oncotype DX RS†   
IHC4-AQUA ‡      
Low 74 12 1 87 85.1% 
Low-mid  45 30 5 80 37.5% 
Mid/High 29 33 41 103 39.8% 
Total 148 75 47 270  
% concordance 50.0% 40.0% 87.2% kappa 0.31 (95% CI: 0.23-0.39) 
 Prosigna    
IHC4       
Low 32 24 6 62 51.6% 
Intermediate 41 40 41 122 32.8% 
High 8 14 48 70 68.6% 
Total 81 78 95 254  
% concordance 39.5% 51.3% 50.5% kappa 0.21 (95% CI: 0.12-0.31) 
 Prosigna   
IHC4-AQUA ‡      
Low 54 24 8 86 62.8% 
Low-mid  25 33 22 80 41.3% 
Mid/High 19 22 61 102 59.8% 
Total 98 79 91 268  
% concordance 55.1% 41.8% 67.0% kappa 0.33 (95% CI: 0.24-0.42) 
 IHC4   
IHC4-AQUA ‡      
Low 47 31 0 78 60.3% 
Low-mid  9 53 9 71 74.6% 
Mid/High 2 33 60 95 63.2% 
Total 58 117 69 244  
% concordance 81.0% 45.3% 87.0% kappa 0.49 (95% CI: 0.40-0.58) 
 
*Only tests that provide three risk categories are included in this analysis. Concordance is calculated as the 
percentage of patients that have been classified in the same risk group by both tests out of the row or column 
total respectively.  
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†The Oncotype DX low risk group is defined as RS<18, the intermediate risk group is defined as RS:18-25 
and the high risk group as RS>25.  
‡The IHC4-AQUA mid risk and high risk groups were combined.   
 
Supplementary Table 6: Kappa statistics and 95% confidence interval (CI) for tests providing risk 
predictions comparing an alternative categorization of low risk versus combined intermediate and 
high risk 
Test 
Kappa statistic (95% CI) 
MammaPrint 
(Low) 
Prosigna 
(Low) 
IHC4 
(Low) 
IHC4-AQUA 
(Low) 
Oncotype DX 
(Recurrence Score <18) 
0·50 (0·41-0·60) 0·28 (0·18-0·38) 0·26 (0·16-0·36) 0·38 (0·28-0·47) 
MammaPrint -- 0·37 (0·28-0·46) 0·23 (0·14-0·31) 0·34 (0·25-0.43) 
Prosigna (Low) -- -- 0·23 (0·11-0·36) 0·37 (0·26-0·49) 
IHC4 (Low) -- -- -- 0·58 (0·46-0·69) 
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Supplementary Table 7: Number of tests agreeing with each test using an alternative categorization of 
low risk versus combined intermediate and high risk categorization* 
Number of other 
tests agreed with 
test 
Oncotype DX, 
No (%) 
Prosigna, 
No (%) 
MammaPrint
, No (%) 
IHC4, No 
No (%) 
IHC4-AQUA, 
No (%) 
4 91 (30.1%) 91 (30.1%) 91 (30.1%) 91 
(30.1%) 
91 (30.1%) 
3 68 (22.6%) 61 (20.2%) 65 (21.5%) 56 
(18.6%) 
51 (16.9%) 
2 67 (22.2%) 81 (26.8%) 59 (19.6%) 60 
(19.9%) 
82 (27.1%) 
1 53 (17.5%) 43 (14.3%) 63 (20.9%) 30 (9.9%) 35 (11.6%) 
0 22 (7.3%) 23 (7.6%) 20 (6.6%) 20 (6.6%) 12 (4.0%) 
Missing 1 (0.3%) 3 (1.0%) 4 (1.3%) 45 
(14.9%) 
31 (10.3%) 
*Only 91 (30.1%) tumours agreed across all tests (23 [7.6%] tumours were low risk; 68 [22.5%] tumours 
were intermediate or high risk).  
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Supplementary Figure 1: Consort diagram 
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Supplementary Figure 2: Scatterplots of the two-by-two comparisons of tests providing risk scores  
 
 
A) Prosigna against Oncotype DX; B) IHC4 against Oncotype DX; C)IHC4-AQUA against Oncotype DX; 
D) IHC4 against Prosigna; E) IHC4-AQUA against Prosigna; F) IHC4-AQUA against IHC4.  Lines on the 
plots represent the predefined cutpoints for categorizing risk scores into low, intermediate, and high risk 
groups.  
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